SELLAS Life Sciences Group, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value
SELLAS Life Sciences Group, Inc. (SLS) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value of $0 for the 9-month period ending 2017-09-30, per its 10-Q filed 2017-11-09.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue · last filed 2017-11-09
- SELLAS Life Sciences Group, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2017-09-30 was $0.00.
- SELLAS Life Sciences Group, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2017-06-30 was $0.00, a 100.00% decline year-over-year.
- SELLAS Life Sciences Group, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2017-03-31 was $0.00, a 100.00% decline year-over-year.
- SELLAS Life Sciences Group, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2016-09-30 was $0.00, a 100.00% decline year-over-year.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 9 month |
|---|---|---|---|
| 2017-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-09 | $0.00 derived: sum of 2 quarters · filed 2017-11-09 | $0.00 10-Q · filed 2017-11-09 |
| 2017-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-14 | $0.00 10-Q · filed 2017-08-14 | |
| 2017-03-31 | $0.00 10-Q · filed 2017-05-10 | ||
| 2016-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-09 | $46.00K derived: sum of 2 quarters · filed 2016-11-09 | $56.00K 10-Q · filed 2016-11-09 |
| 2016-06-30 | $46.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-09 | $56.00K 10-Q · filed 2016-08-09 | |
| 2016-03-31 | $10.00K 10-Q · filed 2016-05-10 | ||
| 2015-09-30 | $36.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-09 | $37.00K derived: sum of 2 quarters · filed 2015-11-09 | $37.00K 10-Q · filed 2015-11-09 |
| 2015-06-30 | $1.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-06 | $1.00K 10-Q · filed 2015-08-06 | |
| 2015-03-31 | $0.00 10-Q · filed 2015-05-07 | ||
| 2014-09-30 | $222.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-05 | $237.00K derived: sum of 2 quarters · filed 2014-11-05 | $13.43M 10-Q · filed 2014-11-05 |
| 2014-06-30 | $15.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-11 | $13.21M 10-Q · filed 2014-08-11 | |
| 2014-03-31 | $13.19M 10-Q · filed 2014-05-06 | ||
| 2013-09-30 | $2.00K derived: 10-Q/A 9 month − 10-Q 6 month · filed 2013-11-07 | $17.00K 10-Q/A · filed 2013-11-07 | |
| 2013-06-30 | $15.00K 10-Q · filed 2013-08-09 | ||
| 2012-09-30 | $10.46K 10-Q · filed 2012-11-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 |